Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab in Relapsed or Refractory Systemic Light Chain Amyloidosis
NCT06292780Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2024
- Primary completion
- Aug 2028
- Countries
- 6
01
Overview
A Phase 2 trial of linvoseltamab in systemic light chain amyloidosis, sponsored by Regeneron Pharmaceuticals. Started Aug 2024; status: recruiting.
02
Drugs
linvoseltamab
03
Conditions
systemic light chain amyloidosis
Beyond the preview
Go deeper on NCT06292780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06292780.